Protherium has raised $17.1M to build out a European network of manufacturing sites for radiopharmaceutical therapies.
The company pitches itself as an independent production partner for radiopharmaceutical developers - the kind of outfit that steps in as drugmakers move from Phase II and Phase III trials toward commercial-scale manufacturing. Protherium's model is built around production modules it offers to those companies, rather than a single owned facility.

















